JPMorgan Chase & Co. Acquires 25,500 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

JPMorgan Chase & Co. increased its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 302.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,936 shares of the company's stock after acquiring an additional 25,500 shares during the quarter. JPMorgan Chase & Co. owned 0.06% of Structure Therapeutics worth $1,489,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of GPCR. Assetmark Inc. grew its holdings in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after buying an additional 719 shares during the last quarter. Quarry LP bought a new stake in Structure Therapeutics during the second quarter worth $79,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Structure Therapeutics by 60.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock valued at $158,000 after purchasing an additional 1,420 shares during the last quarter. Dearborn Partners LLC purchased a new position in shares of Structure Therapeutics in the 3rd quarter worth about $202,000. Finally, Bank Pictet & Cie Europe AG bought a new position in Structure Therapeutics during the third quarter valued at about $206,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on GPCR. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $50.00 target price on the stock. JMP Securities restated a "market outperform" rating and issued a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $81.29.

Structure Therapeutics Stock Up 0.9 %

NASDAQ:GPCR traded up $0.26 during trading hours on Friday, hitting $28.22. 376,109 shares of the company's stock traded hands, compared to its average volume of 801,661. Structure Therapeutics Inc. has a 52 week low of $23.50 and a 52 week high of $62.74. The firm has a market cap of $1.62 billion, a P/E ratio of -38.13 and a beta of -2.78. The business's fifty day simple moving average is $30.02 and its two-hundred day simple moving average is $35.78.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.